Prostate Cancer
Charles L. Sawyers, MD
Memorial Sloan-Kettering Cancer Center
An internationally recognized physician-scientist
  • Was appointed by President Obama to the National Cancer Advisory Board.
  • Recipient of the Breakthrough Prize in Life Sciences that recognizes "excellence in research aimed at curing intractable diseases and extending human life."
  • Recipient of the Lasker DeBakey Clinical Medical Research Award.
  • Played a key role in the development of imatinib (Gleevec) and dasatinib (Sprycel), two drugs that together have transformed chronic myelogenous leukemia from a fatal cancer into one that is nearly always treatable.
  • Helped design the first clinical trial for imatinib, including selecting which patients were most likely to benefit from the drug.
  • Leading a team that uses a new approach in finding a potential drug to attack cancer cells that have become resistant to enzalutamide (Xtandi), a targeted therapy for the treatment of advanced prostate cancer.
Program Information:
Nominate
Sponsor
News
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
Connect: